Compare · ACHV vs NYMX
ACHV vs NYMX
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and Nymox Pharmaceutical Corporation (NYMX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and NYMX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ACHV carries a market cap of $697.7M.
- ACHV has hit the wire 5 times in the past 4 weeks while NYMX has been quiet.
- ACHV has more recent analyst coverage (11 ratings vs 0 for NYMX).
- Company
- Achieve Life Sciences Inc.
- Nymox Pharmaceutical Corporation
- Price
- -
- -
- Market cap
- $697.7M
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 5
- 0
- Recent ratings
- 11
- 0
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, The Bahamas.
Latest ACHV
- SEC Form 10-Q filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
- SEC Form 4 filed by Achieve Life Sciences Inc.
- SEC Form 3 filed by Achieve Life Sciences Inc.
Latest NYMX
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation